Skip to Content
Find More Like This
Return to Search

SERUM BIOMARKERS FOR MELANOMA METASTASIS

United States Patent Application

20120201750
A1
View the Complete Application at the US Patent & Trademark Office
The present invention relates to methods for predicting and evaluating metastasis of solid cancers, such as melanoma, in a subject by measuring serum biomarkers associated with a metastatic phenotype. In particular, the present invention provides a serum gene expression signature that is different between highly aggressive and more metastatic versus less aggressive and less metastatic melanomas by quantitatively measuring the levels of, inter alia, lymphoid-specific helicase (HELLS) and condensing complex subunit 2 (NCAPH) transcripts in a subject.
Ryu, Bungwoo (Las Vegas, NV)
13/ 237,377
September 20, 2011
GOVERNMENT INTEREST STATEMENT [0003] This invention was made with government support under grant number NIH K01 CA113779 awarded by the National Institutes of Health, Nevada Cancer Institute (NVCI) Startup Grant, and DOE DE-FG01-08ER64608 grant awarded by the Department of Energy. The government has certain rights in the invention.